www.praktickelekarenstvi.cz e34 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Nežádoucí účinky kombinované imunoterapie u nádoru ledvin, plic a melanomu and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697. 21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti- -PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. 22. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune- -related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;8(10):2377-2385. 23. Berner F, Bomze D, Diem S, et al. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1043-1047. 24. Willemsen M, Melief CJM, Bekkenk MW, and Luiten RM. Targeting the PD-1/PD-L1 Axis in Human Vitiligo. Front Immunol. 2020;11:579022. 25. Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in CombinationWith Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019;37(11):867-875. 26. Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review. Front Oncol. 2020;10:585311. 27. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773-781. 28. Fujisawa Y, Yoshino K, Otsuka A, et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. J Dermatol Sci. 2018;89(1):60-66. 29. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017;35(7):785-792. 30. Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4(3):374-378. 31. Ishihara H, Takagi T, Kondo T, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol. 2019;37(6):355.e21-355.e29. 32. Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7(1):341. 33. Fiala O, Sorejs O, Sustr J, et al. Immune-related Adverse Effects and Outcome of Patients With Cancer TreatedWith Immune Checkpoint Inhibitors. Anticancer Res 2020;40(3):1219–1227. 34. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3mg/kg in patients with unresectable or metastatic melanoma: a randomised, double- -blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611-622. 35. Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. Journal for immunotherapy of cancer. 2016;4:72-72.
RkJQdWJsaXNoZXIy NDA4Mjc=